Chronic lymphocytic leukemia (CLL) is a genetically, epigenetically, and clinically heterogeneous disease, with relatively few genetic alterations. The Bruton tyrosine kinase inhibitor ibrutinib provides effective treatment for the vast majority of CLL patients, and while not curative, ibrutinib provides a potential avenue to pharmacologically exploit vulnerabilities of this disease.
Genome-wide chromatin accessibility profiling is used to define the underlying regulatory programs of epigenome deregulation in CLL. Enriched with thorough clinical annotation, flow cytometry, CHIPmentation, transcriptomic profiling and/or chemosensitivity profiling, these datasets enable the dissection of patient-to-patient variability, the identification of consistent regulatory programs shared across patients and its dynamics during ibrutinib treatment course, and the discovery of potential new drug vulnerabilities.
* shared first or shared senior authorship